| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
26,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0055 - $0.0055 |
|
| Level
I Sector: |
Basic Materials |
| Level
II Sector: |
Chemicals |
| Level
III Sector: |
Specialty Chemicals |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ABVC BioPharma is a clinical stage biopharmaceutical company. Co.'s wholly owned subsidiaries, American BriVision Corporation, focuses on the development of ABV-1701 Vitreous Substitute for Vitrectomy. Through its another wholly owned subsidiary, BioLite Holding Inc., Co. conducts clinical research and trials of various drug candidates, including: ABV-1504 for the treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of Triple Negative Breast Cancer, ABV-1703 for the treatment of Pancreatic Cancer, ABV-1702 to treat Myelodysplastic syndromes and ABV-1601 Depression in Cancer Patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stromback Richard Dean |
Director |
– • • |
2009-01-23 |
4 |
S |
$1.00 |
$4,000,000 |
D/D |
(4,000,000) |
10,637,500 |
|
- |
|
| Smith J.b. |
Director |
– • – |
2008-09-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,503,305 |
|
- |
|
| Stromback Richard Dean |
CEO |
• • • |
2008-08-18 |
4 |
S |
$0.00 |
$0 |
D/D |
(1,500,000) |
14,637,500 |
|
- |
|
| Ramsey Sally Judith |
VP New Product Development |
• – – |
2007-07-30 |
4/A |
B |
$0.00 |
$0 |
D/D |
3,000,000 |
3,000,000 |
2.66 |
- |
|
| Krotine Frank Thomas |
CEO, PresidentOfficer |
• • – |
2007-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| Ramsey Sally Judith |
Vice PresidentOfficer |
• – – |
2007-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,000,000 |
|
- |
|
| Stromback Richard Dean |
Director |
– • • |
2007-07-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
65,000 |
|
- |
|
| Stromback Richard Dean |
Director |
– • • |
2007-07-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,135,000 |
|
- |
|
33 Records found
|
|
Page 2 of 2 |
|
|
